Get the Stockscreener App
1.83
1.67%
0.03
Pre-market:
1.82
-0.01
-0.55%
Nkarta Inc stock is traded at $1.83, with a volume of 691.00K.
It is up +1.67% in the last 24 hours and down -8.50% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$1.80
Open:
$1.77
24h Volume:
691.00K
Relative Volume:
1.24
Market Cap:
$141.21M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.7625
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
+4.57%
1M Performance:
-8.50%
6M Performance:
-22.13%
1Y Performance:
-71.69%
1-Day Range:
$1.7401
$1.835
1-Week Range:
$1.68
$1.84
52-Week Range:
$1.31
$8.23
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.83 | 141.21M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Nkarta (NASDAQ:NKTX) Stock Price Up 3% – Here’s What Happened - Defense World
Nkarta (NASDAQ:NKTX) Price Target Lowered to $14.00 at Mizuho - Defense World
Nkarta (NKTX) Maintains Outperform Rating as Mizuho Lowers Price Target | NKTX Stock News - GuruFocus
Two Sigma Investments LP Reduces Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta price target lowered to $14 from $16 at Mizuho - TipRanks
Nkarta (NKTX) Price Target Reduced by Mizuho | NKTX Stock News - GuruFocus
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Wellington Management Group LLP - Defense World
Bank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Two Sigma Advisers LP Acquires New Stake in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta Names Shawn Rose as Chief Medical Officer - marketscreener.com
Nkarta Announces Leadership Change with New CMO - TipRanks
NKTX Appoints Shawn Rose as New Chief Medical Officer | NKTX Stock News - GuruFocus
Nkarta appoints Shawn Rose as CMO, head of R&D - TipRanks
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of - GlobeNewswire
Nkarta Taps Sotyktu, Stelara Developer as New CMO to Lead Autoimmune Disease Push - Stock Titan
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Nuveen Asset Management LLC - Defense World
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus - Yahoo Finance
ProShare Advisors LLC Invests $45,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Deutsche Bank AG Has $107,000 Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
BNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade - MSN
Equities Analysts Issue Forecasts for Nkarta FY2025 Earnings - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for Nkarta - Defense World
Price T Rowe Associates Inc. MD Acquires 7,030 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
William Blair Comments on Nkarta’s Q2 Earnings (NASDAQ:NKTX) - Defense World
Nkarta (NASDAQ:NKTX) Earns “Market Perform” Rating from William Blair - Defense World
Needham & Company LLC Lowers Nkarta (NASDAQ:NKTX) Price Target to $10.00 - Defense World
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Dimensional Fund Advisors LP Has $1.42 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Stifel Financial Corp - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. Reports Q1 2025 Financial Results - TipRanks
Nkarta stock rating downgraded at William Blair to Market Perform By Investing.com - Investing.com South Africa
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Benzinga
Nkarta (NKTX) Experiences Downgrade Amid Clinical Protocol Changes | NKTX Stock News - GuruFocus
NKTX's Strategic Moves to Reach Clinical Milestones and Extend C - GuruFocus
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX S - GuruFocus
Needham Maintains 'Buy' Rating on Nkarta (NKTX) as Price Target Adjusts | NKTX Stock News - GuruFocus
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX Stock News - GuruFocus
William Blair Downgrades Nkarta to Market Perform From Outperform - marketscreener.com
Nkarta stock rating downgraded at William Blair to Market Perform - Investing.com
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
NKTX's Strategic Moves to Reach Clinical Milestones and Extend Cash Runway | NKTX Stock News - GuruFocus
Nkarta's $351.9M War Chest Funds Operations Until 2029 as Clinical Trials Expand in Autoimmune Diseases - Stock Titan
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Wells Fargo & Company MN - Defense World
Barclays PLC Has $674,000 Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Financial Snapshot: Analyzing Nkarta Inc (NKTX)’s Key Ratio Metrics - DWinneX
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shook David | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
8,638 |
19,004 |
190,955 |
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
| Hager Alicia J. | Chief Legal Officer |
Jul 16 '24 |
Sale |
8.00 |
3,396 |
27,168 |
103,819 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):